Logo image of ARVN

ARVINAS INC (ARVN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ARVN - US04335A1051 - Common Stock

12.69 USD
-0.29 (-2.23%)
Last: 12/11/2025, 1:01:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ARVN. ARVN was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of ARVN is average, but there are quite some concerns on its profitability. ARVN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ARVN had negative earnings in the past year.
ARVN had a negative operating cash flow in the past year.
ARVN had negative earnings in each of the past 5 years.
ARVN had negative operating cash flow in 4 of the past 5 years.
ARVN Yearly Net Income VS EBIT VS OCF VS FCFARVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

ARVN's Return On Assets of -6.92% is fine compared to the rest of the industry. ARVN outperforms 70.68% of its industry peers.
ARVN has a Return On Equity of -10.35%. This is in the better half of the industry: ARVN outperforms 73.82% of its industry peers.
Industry RankSector Rank
ROA -6.92%
ROE -10.35%
ROIC N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ARVN Yearly ROA, ROE, ROICARVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARVN Yearly Profit, Operating, Gross MarginsARVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

ARVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARVN has been increased compared to 1 year ago.
ARVN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ARVN has an improved debt to assets ratio.
ARVN Yearly Shares OutstandingARVN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARVN Yearly Total Debt VS Total AssetsARVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

ARVN has an Altman-Z score of 0.17. This is a bad value and indicates that ARVN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.17, ARVN is in line with its industry, outperforming 46.60% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that ARVN is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.00, ARVN is doing good in the industry, outperforming 62.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.17
ROIC/WACCN/A
WACC9.23%
ARVN Yearly LT Debt VS Equity VS FCFARVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

ARVN has a Current Ratio of 5.70. This indicates that ARVN is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.70, ARVN is doing good in the industry, outperforming 66.49% of the companies in the same industry.
A Quick Ratio of 5.70 indicates that ARVN has no problem at all paying its short term obligations.
ARVN has a Quick ratio of 5.70. This is in the better half of the industry: ARVN outperforms 67.54% of its industry peers.
Industry RankSector Rank
Current Ratio 5.7
Quick Ratio 5.7
ARVN Yearly Current Assets VS Current LiabilitesARVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.66% over the past year.
ARVN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.47%.
Measured over the past years, ARVN shows a very strong growth in Revenue. The Revenue has been growing by 43.69% on average per year.
EPS 1Y (TTM)82.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.41%
Revenue 1Y (TTM)10.47%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%-59.08%

3.2 Future

Based on estimates for the next years, ARVN will show a small growth in Earnings Per Share. The EPS will grow by 7.50% on average per year.
ARVN is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.00% yearly.
EPS Next Y70.99%
EPS Next 2Y-5.26%
EPS Next 3Y-3.01%
EPS Next 5Y7.5%
Revenue Next Year9.65%
Revenue Next 2Y-40.1%
Revenue Next 3Y-29.39%
Revenue Next 5Y-4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ARVN Yearly Revenue VS EstimatesARVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ARVN Yearly EPS VS EstimatesARVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARVN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARVN Price Earnings VS Forward Price EarningsARVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARVN Per share dataARVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

ARVN's earnings are expected to decrease with -3.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.26%
EPS Next 3Y-3.01%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARVINAS INC

NASDAQ:ARVN (12/11/2025, 1:01:01 PM)

12.69

-0.29 (-2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-09 2026-02-09/amc
Inst Owners96.03%
Inst Owner Change-2.67%
Ins Owners2.5%
Ins Owner Change1.79%
Market Cap814.95M
Revenue(TTM)312.30M
Net Income(TTM)-58.40M
Analysts74.62
Price Target13.08 (3.07%)
Short Float %13.77%
Short Ratio3.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.38%
Min EPS beat(2)18.03%
Max EPS beat(2)40.73%
EPS beat(4)4
Avg EPS beat(4)79.1%
Min EPS beat(4)18.03%
Max EPS beat(4)218.09%
EPS beat(8)7
Avg EPS beat(8)41.08%
EPS beat(12)9
Avg EPS beat(12)29.09%
EPS beat(16)9
Avg EPS beat(16)16.23%
Revenue beat(2)1
Avg Revenue beat(2)23.18%
Min Revenue beat(2)-27.7%
Max Revenue beat(2)74.06%
Revenue beat(4)2
Avg Revenue beat(4)95.07%
Min Revenue beat(4)-27.7%
Max Revenue beat(4)345.02%
Revenue beat(8)4
Avg Revenue beat(8)34.48%
Revenue beat(12)7
Avg Revenue beat(12)34.53%
Revenue beat(16)10
Avg Revenue beat(16)34.32%
PT rev (1m)3.1%
PT rev (3m)-1.8%
EPS NQ rev (1m)10.64%
EPS NQ rev (3m)18.51%
EPS NY rev (1m)35.21%
EPS NY rev (3m)37.48%
Revenue NQ rev (1m)-1.09%
Revenue NQ rev (3m)-1.21%
Revenue NY rev (1m)12.69%
Revenue NY rev (3m)5.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.61
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-3.07
Fwd EYN/A
FCF(TTM)-5.13
FCFYN/A
OCF(TTM)-5.1
OCFYN/A
SpS4.86
BVpS8.79
TBVpS8.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -6.92%
ROE -10.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.82%
Cap/Sales 0.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.7
Quick Ratio 5.7
Altman-Z 0.17
F-Score6
WACC9.23%
ROIC/WACCN/A
Cap/Depr(3y)69.16%
Cap/Depr(5y)101.08%
Cap/Sales(3y)3.18%
Cap/Sales(5y)9.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.41%
EPS Next Y70.99%
EPS Next 2Y-5.26%
EPS Next 3Y-3.01%
EPS Next 5Y7.5%
Revenue 1Y (TTM)10.47%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%-59.08%
Revenue Next Year9.65%
Revenue Next 2Y-40.1%
Revenue Next 3Y-29.39%
Revenue Next 5Y-4%
EBIT growth 1Y82.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.25%
EBIT Next 3Y8.93%
EBIT Next 5YN/A
FCF growth 1Y3.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.53%
OCF growth 3YN/A
OCF growth 5YN/A

ARVINAS INC / ARVN FAQ

What is the ChartMill fundamental rating of ARVINAS INC (ARVN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ARVN.


What is the valuation status of ARVINAS INC (ARVN) stock?

ChartMill assigns a valuation rating of 0 / 10 to ARVINAS INC (ARVN). This can be considered as Overvalued.


Can you provide the profitability details for ARVINAS INC?

ARVINAS INC (ARVN) has a profitability rating of 1 / 10.


How financially healthy is ARVINAS INC?

The financial health rating of ARVINAS INC (ARVN) is 4 / 10.